Press Releases

Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the initiation of a Phase 1b multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient. UPB-101 is a monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation. TSLP is a cytokine and a key driver of inflammatory response in asthma and other allergic and inflammatory dis

On August 5, 2022, Legend Capital portfolio company MicuRx Pharmaceuticals, a scarce enterprise in super antibiotic, was successfully listed on the STAR Market. MicuRx Pharmaceuticals issued 130,000,000 shares this time, accounting for 19.84% of the total share capital after the issuance. The total amount of funds raised is expected to be about RMB 960 million at the issue price of 8.16 yuan per share. MicuRx Pharmaceuticals is an innovative drug company focusing on novel therapeuti

Wie Pharma Tech Holding SA heute mitteilte, hat sich das Unternehmen eine Investition in Höhe von 30 Millionen CHF von LDA Capital Ltd zur Unterstützung seiner Portfolioinvestitionen gesichert. LDA Capital Ltd ist eine globale Investorengruppe mit Expertise in grenzüberschreitenden Transaktionen, einschließlich Agrar-, Agrartechnik- und CBD-Branchen. PTH, eine 2019 gegründete Holdinggesellschaft mit Sitz in Lugano (Schweiz), investiert in innovative Unterne

CinCor Pharma, Inc.  a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases, today announced that it has launched an underwritten public offering of 6,000,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission. CinCor may, in lieu of common stock, offer and sell to certain investors pre-funded warra

Genmab A/S and BioNTech SE today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. Under the expansion, Genmab and BioNTech will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint development of bispecific cancer antibodies aimed at improving immunotherapy options

Ascletis Pharma Inc. today announces the completion of first patient dosing in the U.S. Phase I clinical trial of ASC61, an oral PD-L1 small molecule inhibitor prodrug, for treatment of advanced solid tumors. This U.S. Phase I trial is a dose-escalation study to evaluate the safety and tolerability of ASC61 as well as to define the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ASC61 in patients with advanced solid tumors who have disease progression during or f

BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs. X-Chem will leverage its powerful DEL technology platform and large collection of novel, diverse lead- and drug-like

Model N, Inc.the leader in revenue optimization and compliance, today announced the launch of Transparency Talks, a new, three-part education series for pharmaceutical companies that tackles the topic of price transparency regulations for prescription drugs. Transparency Talks will bring together leaders from Model N, Pfizer and Global Pricing Innovations (GPI) to explore state drug pricing laws and regulations, as well as facilitate a discussion on trends, best practices and innovative appro

flipMD, the first-physician-only consulting services platform offering non-clinical medical expertise to industry partners and powered by GoodRx, has announced the launch of its new recruiting platform, flipMD Hire (Hire). Hire allows healthcare companies-from hospitals, to private practices, to pharma, biotech and beyond-to post full-time and temporary clinical and non-clinical positions for physicians, expanding flipMD’s platform beyond work-for-hire consulting engagements.

Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1) across three distinct platforms: Oral Delivery, Therapeutics, and Regenerative Medicine, announced today that the Integrated Islet Distribution Program (IIDP) has selected it as an approved Islet Isolation Center (IIC). The (IIDP) is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), an institute within the U.S. Department of Health and Human Services' N